Gilead Sciences Beats Q4 EPS Forecast

[cafead]

via

• Adjusted EPS of $1.90 topped analyst expectations of $1.74.
• Q4 revenue reached $7.57 billion, surpassing forecasts of $7.15 billion.
• HIV product sales showed substantial growth, climbing 16% to $5.5 billion due to high demand and inventory benefits.

article source